Introduction
Brand name: Telget‑BR 500
Manufacturer: Astemax Biotech Pvt. Ltd.
Composition: Teneligliptin 20 mg + Metformin hydrochloride 500 mg sustained‑release (SR) bilayered tablet
Telget‑BR 500 is a bilayered, fixed‑dose combination tablet for type 2 diabetes mellitus, combining a DPP‑4 inhibitor (teneligliptin) with extended‑release metformin in a single dose once daily.
Key ingredients and mechanism
Teneligliptin 20 mg
A DPP‑4 inhibitor that increases active GLP‑1, enhancing glucose‑dependent insulin secretion and suppressing glucagon, thereby lowering fasting and post‑prandial blood glucose with low hypoglycaemia risk.
Metformin hydrochloride 500 mg (SR)
Biguanide that reduces hepatic glucose output, improves peripheral insulin sensitivity, and modestly reduces body weight and HbA1c, delivered in a sustained‑release form to improve GI tolerability.
Main indications
Monotherapy or add‑on therapy in patients with type 2 diabetes where dual‑mechanism action (incretin‑based plus metformin) is desired.
Particularly useful in overweight or obese patients needing weight‑neutral or weight‑advantageous therapy and in those with metformin‑intolerance at higher immediate‑release doses.
Typical use and precautions
Usual dose: 1 Telget‑BR 500 tablet once daily, usually with the evening meal, as per local prescribing guidelines and individual glycaemic response
Astemax positions Telget‑BR 500 as a WHO‑GMP‑compliant, bilayered, once‑daily dual‑mechanism tablet suited for diabetologists and physicians managing type 2 diabetes with a focus on improved adherence and GI‑tolerability via SR metformin.
